On October 30, 2025, Ultragenyx Pharmaceutical Inc. announced that the first patient has been dosed in the Aurora study for GTX-102, focusing on Angelman syndrome. The study will enroll about 60 participants from ages one to 65, expanding treatment options compared to the previous Aspire study.